- Home
- AMSC vs AUPH Comparison
AMSC vs AUPH Comparison
Compare AMSC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMSC | AUPH |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | Canada |
| Employees | 400 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.1B |
| IPO Year | 2012 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AMSC | AUPH |
|---|---|---|
| Price | $30.33 | $15.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $61.75 | $17.86 |
| AVG Volume (30 Days) | 618.7K | ★ 739.1K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1806.25 | ★ 5075.00 |
| EPS | 0.20 | ★ 0.53 |
| Revenue | $900,000.00 | ★ $283,055,000.00 |
| Revenue This Year | $22.95 | $15.83 |
| Revenue Next Year | $15.15 | $21.30 |
| P/E Ratio | $159.20 | ★ $29.51 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $24.87 | $10.92 |
| 52 Week High | $70.49 | $19.25 |
Technical Indicators
Market Signals| Indicator | AMSC | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 41.11 |
| Support Level | $29.22 | $15.65 |
| Resistance Level | $31.88 | $16.33 |
| Average True Range (ATR) | 1.22 | 0.35 |
| MACD | 0.22 | -0.12 |
| Stochastic Oscillator | 55.18 | 17.75 |
Price Performance
Historical ComparisonAbout AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.